|
|
|
|
|
|
|
|
|
19.02.26 - 22:33
|
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire EN)
|
|
|
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026....
|
|
|
|
|
28.01.26 - 12:01
|
AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! (Der Aktionaer)
|
|
|
Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten von Piper Sandler sehen in einer aktuellen Studie das Ende der Fahnenstange bei Weitem noch nicht erreicht....
|
|
|
|
|
22.01.26 - 04:33
|
BioAge Announces Pricing of Upsized $115.0 Million Public Offering (GlobeNewswire EN)
|
|
|
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. All of the shares of common stock are being offered by BioAge....
|
|
|
|
|
20.01.26 - 22:03
|
BioAge Announces Proposed Public Offering (GlobeNewswire EN)
|
|
|
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock are being offered by BioAge. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering....
|
|
|
|
|
|
|
15.01.26 - 09:45
|
BioAge Labs: NBC-Empfehlung knallt auf +449% Rendite! (Sharedeals)
|
|
|
Die Aktie von BioAge Labs setzt ihre beeindruckende Erfolgsgeschichte fort. Nachdem sich der Wert der letztjährigen No Brainer Club-Empfehlung innerhalb weniger Monate bereits mehr als vervierfachen konnte, kam es diese Woche zu einer erneuten Kursrallye. Bereits im letzten Jahr hatte BioAge Labs NBC-Anlegern enorme Renditen beschert. Ausgehend von der Kaufzone bis 4,30 US$ vervielfachte sich […]
The post BioAge Labs: NBC-Empfehlung knallt auf +449% Rendite! first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
07.01.26 - 00:00
|
Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! (Sharedeals)
|
|
|
Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie nachbörslich noch einmal fast 60% drauflegt. Seit der ersten NBC-Empfehlung vor gut einem Jahr stehen damit über +1.000% Kursgewinn zu Buche. Ventyx vor Milliardenübernahme Nach einem Bericht […]
The post Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! first appeared on sharedeals.de....
|
|
|
23.12.25 - 21:27
|
Goldman′s Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors (ZeroHedge)
|
|
|
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors
There are just nine days left in the year, and this year has flown by.
We've delivered readers a steady stream of 2026 outlooks over the past few days and weeks, and next up is a year-ahead catalyst list from Goldman Sachs' small-cap biotech stock coverage.
Goldman analysts, led by Corinne Johnson, held their third "Year-Ahead" Catalyst Clinic, highlighting significant clinical catalysts for small-cap biotech companies (market caps under $3 billion) in their stock coverage universe.
Featured companies in the Catalyst Clinic included AbCellera Biologics, Allogene Therapeutics, Apogee Therapeutics, BioAge Labs, Entrada Therapeutics, Gossamer Bio, Gubra, Lyell Immunopharma, Recursion Pharmaceuticals, Sana Biotechnology, Sionna Therapeutics, Sera Prognostics, Tyra Biosciences, Viralgen, and Viridian Therapeutics.
Johnson said the sentiment from the event was mostly positive, with several names showing cl...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
